<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987711</url>
  </required_header>
  <id_info>
    <org_study_id>SAFE-D-01</org_study_id>
    <nct_id>NCT03987711</nct_id>
  </id_info>
  <brief_title>Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis</brief_title>
  <acronym>SAFE-D</acronym>
  <official_title>Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis (SAFE-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Michael's Hospital (Toronto, Canada)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The George Institute for Global Health (Sydney, Australia)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevention of atrial fibrillation related thromboembolism in the dialysis population is
      unclear. While the practice of anticoagulation appears favorable in patients with
      mild-to-moderate chronic kidney disease, no patients with severe chronic kidney disease
      (estimated glomerular filtration rate &lt;25 ml/min), and specifically those receiving dialysis,
      have been included in randomized trials.Moreover, the effect of anticoagulation in the
      dialysis population may fundamentally differ from those studied in clinical trials.
      Accordingly, characterization of the optimal management strategy to reduce the risk of stroke
      and systemic embolism in patients with atrial fibrillation receiving dialysis is a priority.
      The overall goal of this pilot trial is to evaluate the feasibility of conducting a
      randomized controlled trial comparing anticoagulation strategies in patients with atrial
      fibrillation receiving dialysis (either hemodialysis or peritoneal dialysis).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment of the target population within 2 years</measure>
    <time_frame>2 years from start of trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>At least 80% of randomized participants remain in the trial and on the allocated study treatment at the end of the 26-week study period.</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients randomized to warfarin achieving a Time in the Therapeutic Range (TTR) &gt;65%.</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&gt;95% of randomized patients adhere to the enrollment criteria with respect to atrial fibrillation or atrial flutter</measure>
    <time_frame>End of trial</time_frame>
    <description>Through adjudication of ECGs or other cardiac diagnostics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>26 weeks</time_frame>
    <description>As defined by the International Society of Thrombosis and Haemostasis (ISTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant non-major bleeding</measure>
    <time_frame>26 weeks</time_frame>
    <description>As defined by the International Society of Thrombosis and Haemostasis (ISTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke and systemic embolism</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular events not related to dialysis access</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events of special interest related to dialysis access, the dialysis procedure or the oral anticoagulants</measure>
    <time_frame>26 weeks</time_frame>
    <description>Thrombosis of fistula or graft; fistula or graft abandonment; thrombosis of dialysis catheter; red blood cell transfusions; calciphylaxis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No oral anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals in this arm will be exposed to a treatment strategy in which no oral anticoagulation is prescribed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.</description>
    <arm_group_label>Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No oral anticoagulation</intervention_name>
    <description>No oral anticoagulation</description>
    <arm_group_label>No oral anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years.

          2. Receiving maintenance hemodialysis or peritoneal dialysis for &gt; 90 days.

          3. History of AF or atrial flutter as defined by:

             (i) AF or atrial flutter on a 12 lead ECG at enrollment, and not due to a reversible
             cause, or (ii) AF or atrial flutter documented on two separate occasions, not due to a
             reversible cause, at least 1 day apart prior to enrollment. AF or atrial flutter may
             be documented by ECG, or as an episode lasting at least 30 seconds on a rhythm strip
             or Holter recording, or more than 30 minutes if using pacemaker or implantable
             cardioverter defibrillator (ICD) recordings, or (iii) AF or atrial flutter documented
             on one occasion, not due to a reversible cause, prior to enrollment and being treated
             with an oral anticoagulant for AF or atrial flutter at enrollment. [AF or atrial
             flutter may be documented by ECG, or as an episode lasting at least 30 seconds on a
             rhythm strip or Holter recording, or more than 30 minutes if using pacemaker or
             implantable cardioverter defibrillator (ICD) recordings, or mentioned in the medical
             record], or (iv) AF or atrial flutter documented on one occasion on ECG, not due to a
             reversible cause, prior to enrollment and at least one more episode of AF or atrial
             flutter mentioned in the medical record, or (v) AF or atrial flutter documented on one
             occasion in a cardiologist report, not due to a reversible condition, prior to
             enrollment.

          4. Satisfying CHADS-65 criteria: i) Age ≥65 or ii) Age &lt;65 and one of: hypertension,
             diabetes mellitus, congestive heart failure, stroke/transient ischemic attack or
             peripheral embolism.

        Exclusion Criteria:

          1. Moderate or severe mitral stenosis.

          2. Conditions other than non-valvular atrial fibrillation that require oral
             anticoagulation, such as mechanical prosthetic valve, deep venous thrombosis, or
             pulmonary embolism.

          3. Need for aspirin at a dose &gt; 165 mg a day, or need for aspirin in combination with
             P2Y12 antagonist therapy.

          4. Need for an interacting drug which precludes the safe use of apixaban.

          5. Life expectancy &lt; 6 months.

          6. Scheduled live-donor kidney transplant in the next 6 months.

          7. A woman who is pregnant or breastfeeding or unwilling to pursue methods of
             contraception if &lt; 12 months since the last menstrual period.

          8. Co-enrollment in a clinical trial where the intervention is deemed to interfere with
             the adherence, safety or efficacy of the intervention provided herein.

          9. Patient's attending physician(s) (e.g., nephrologist and/or cardiologist and/or
             neurologist) believes that oral anticoagulation is absolutely mandated.

         10. Patient's attending physician(s) (e.g., nephrologist and/or cardiologist and/or
             neurologist) believes that oral anticoagulation is absolutely contraindicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziv Harel</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ron Wald</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziv Harel</last_name>
    <phone>416-360-4000</phone>
    <phone_ext>8462</phone_ext>
    <email>ziv.harel@unityhealth.to</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ron Wald</last_name>
    <phone>416-867-3703</phone>
    <email>ron.wald@unityhealth.to</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The George Institute for Global Health</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brendan Smyth</last_name>
      <phone>+61 2 8052 4658</phone>
      <email>bsmyth@georgeinstitute.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Sunil Badve</last_name>
      <phone>+61 2 8052 4636</phone>
      <email>sbadve@georgeinstitute.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority, QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karthik Tennankore</last_name>
      <phone>902-473-2099</phone>
      <email>karthikk.tennankore@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Karthik Tennankore</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Clark</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Soroka</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Vinson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Steele</last_name>
      <phone>905-576-8711 x33200</phone>
      <email>asteele@lh.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Steele</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy Barrese</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Buldo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Wei</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rey Acedillo</last_name>
      <phone>807-684-7566</phone>
      <email>acedillr@tbh.net</email>
    </contact>
    <investigator>
      <last_name>Rey Acedillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nasim Shahbazi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Health Toronto, at its St. Michael's Hospital site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziv Harel</last_name>
      <phone>416-360-4000</phone>
      <phone_ext>8462</phone_ext>
      <email>ziv.harel@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>Ziv Harel</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Wald</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Beaubien-Souligny</last_name>
      <phone>514-377-3733</phone>
      <email>william.beaubien@gmail.com</email>
    </contact>
    <investigator>
      <last_name>William Beaubien-Souligny</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Granger-Vallée</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Blum</last_name>
      <phone>514-340-8222 x24249</phone>
      <email>daniel.blum@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Blum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Madore</last_name>
      <phone>514-338-2222</phone>
      <email>f.madore@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>François Madore</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rémi Goupil</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Québec - Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Mac-Way</last_name>
      <phone>418-525-4444 x15464</phone>
      <email>fabrice.mac-way@chudequebec.ca</email>
    </contact>
    <investigator>
      <last_name>Fabrice Mac-Way</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Desmeules</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu Rousseau-Gagnon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien Xavier Joncas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhanu Prasad</last_name>
      <phone>306-352-3018</phone>
      <email>bprasad@sasktel.net</email>
    </contact>
    <investigator>
      <last_name>Bhanu Prasad</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Payam Dehghani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

